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Abstract
Purpose Chronic diseases are associated with impaired health-related quality of life (HRQoL) outcomes. Comparison of 
HRQoL outcomes between different diseases and with the general population is of major importance to health economists, 
epidemiologists, clinicians, and policy makers. The aim of this systematic literature review was to develop a catalogue with 
EQ-5D scores in chronic non-communicable diseases, and to compare these scores with reference values from the general 
population.
Methods MEDLINE, Embase, and Web of Science were systematically searched independently by two reviewers. Studies 
were included if they reported mean EQ-5D index values for the adult population and if these scores were compared with 
the general population. The QualSyst tool for quantitative research was used for quality appraisal.
Results Two hundred and seven articles met the inclusion criteria. An extensive catalogue summarizes the EQ-5D scores 
in a wide variety of chronic diseases. Mean EQ-5D index values ranged between − 0.20 and 1. Lower EQ-5D scores are 
reported in chronic diseases compared to the general population, specifically in neurological disorders. Most of the diseases 
demonstrate a substantial disutility, although a minority of diseases have equal or even higher index scores than the general 
population.
Conclusion A comprehensive, international catalogue has been developed to provide EQ-5D index scores for diverse chronic 
diseases compared with reference values based on the available literature. The catalogue gives a clear overview of the exist-
ing EQ-5D scores and can be rapidly accessed by researchers worldwide for different applications such as health economic 
evaluations, decision making, resource allocation, and other policy objectives. Future studies should focus on unexamined 
diseases and specific patient groups to expand the evidence base on HRQoL in chronic diseases.
Keywords Health-related quality of life · Utility · EQ-5D · Catalogue · Chronic disease · Cost-effectiveness analysis · 
Health economic evaluation · Systematic review
Introduction
With an estimated 36 million deaths annually, chronic 
diseases remain the leading cause of mortality worldwide 
[1, 2]. Furthermore, chronic diseases are associated with 
a substantial burden of disease for the patients, their car-
egivers, and the society as a whole [3, 4]. The burden of 
disease is commonly assessed by disability-adjusted life 
years (DALYs) with more than half of the DALYs world-
wide being caused by chronic diseases [4]. During the past 
decades, patients’ health-related quality of life (HRQoL) has 
gained importance as a key health outcome indicator, specif-
ically in chronically ill patients, due to improved care which 
contributes to the increase of lifespan [3]. HRQoL captures 
patients’ self-perceived impact of a medical condition, its 
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symptoms and treatment referring to physical, mental, and 
social well-being, compared to what patients believe to be 
ideal [3, 5]. The number of studies exploring the relationship 
between chronic diseases and HRQoL is increasing. These 
studies show a significant decrease in HRQoL in chronic 
diseases and indicate HRQoL as an important predictor of 
mortality and morbidity [5–8].
Hence, in addition to mortality and morbidity, patients’ 
HRQoL is of major concern to policy makers. HRQoL out-
comes are often included in health economic evaluations 
when calculating quality-adjusted life years (QALYs) [9, 
10]. QALYs combine the impact of a disease on both the 
quantity and quality of life [11]. To calculate QALYs, pref-
erence-based utility scores are required ranging from zero 
(death) to one (perfect health) [11–13]. These preference-
based utilities can be derived from the widely used Euro-
Qol Five Dimensions (EQ-5D) instrument. The EQ-5D is a 
standardized generic instrument for describing and valuing 
HRQoL. The instrument allows to calculate utility scores 
based on country-specific value sets or scoring algorithms, 
which reflect the preference for a health state of the gen-
eral population in a specific country [14]. Compared to 
disease-specific HRQoL instruments, generic instruments 
can be used across different patient groups allowing com-
parison in HRQoL loss across diseases [15]. Some initiatives 
to summarize HRQoL data in a specific disease area have 
been established, but to date, a comprehensive overview of 
HRQoL data, particularly EQ-5D data in different chronic 
diseases across countries, is lacking [16].
A comparison of EQ-5D index scores can facilitate 
health economic evaluations and epidemiologic research. 
Therefore, the aim of this review is to develop a catalogue 
of EQ-5D index scores by systematically reviewing the cur-
rently available evidence on EQ-5D index scores across 
patients with chronic diseases, and to compare these scores 
with reference values from the general population. Devel-
oping a catalogue as such would be of major interest to 
researchers and decision makers in their search for useful 
EQ-5D data without the difficulty of primary data collec-
tion. The availability of a comprehensive and easy accessible 
EQ-5D catalogue will enable more efficient cost-effective-
ness analysis, decision making, and resource allocation. This 
review does not aim to be applied in Global Burden of Dis-
ease context since decomposing patient-level burden to the 
underlying diseases or health states, presented by DALYs, 
is beyond the scope of this review [17].
Methods
The methodology as described in the Cochrane Handbook 
for Systematic Reviews of Interventions was used [18]. The 
protocol was registered on PROSPERO (https ://www.crd.
york.ac.uk/prosp ero) with the following registration number: 
CRD42018104110.
Search strategy
A systematic literature search was conducted until May 
2019. To identify all relevant studies, three electronic data-
bases were systematically searched: MEDLINE (using Pub-
Med interface), Embase (using embase.com interface), and 
Web of Science.
Details of the search strategies are illustrated in Online 
Resource 1. The search strategy was peer reviewed by 
an information expert (NP) and evaluated using the Peer 
Review of Electronic Search Strategies (PRESS) checklist 
[19].
Study eligibility criteria
The following eligibility criteria were used:
(1) The population of interest had to have a medically con-
firmed or self-reported diagnosis of one or more non-
communicable chronic diseases. Infectious diseases 
were excluded.
(2) The study had to include adults (≥ 18 years).
(3) The study had to evaluate preference-based utilities 
derived from the three-level (EQ-5D-3L) or five-level 
(EQ-5D-5L) version of the EQ-5D. The utilities had to 
be presented as means. Mapped utilities, for example 
derived from the 36-item Short Form Health Survey 
(SF-36), were excluded because they may not corre-
spond with directly obtained EQ-5D scores.
(4) The study had to compare the EQ-5D index scores 
with those of the general or the healthy population. 
The former includes both healthy and unhealthy people, 
whereas the latter includes people without any disease.
(5) If no full text was available, the study was excluded.
(6) Abstracts and full texts in any other language than Eng-
lish were excluded.
(7) Only observational studies were recognized as appro-
priate. Experimental study designs were excluded.
(8) No restrictions by publication date were implemented.
Study selection
Study selection was performed using the web application 
Rayyan (https ://rayya n.qcri.org). After removing duplicates, 
two independent reviewers (ER and LVW) were blinded 
from each other’s decision and excluded irrelevant studies, 
based on title and abstract. Next, all full-text records of the 
remaining references were independently assessed by both 
reviewers. Disagreements were resolved by discussion and 
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if consensus could not be achieved, a third review author 
(DDS) was consulted.
Quality assessment
The QualSyst tool for quantitative research was used for 
quality appraisal [20]. This checklist consists of a 14-item 
scale with questions related to the research question, study 
design, sampling method, subject characteristics, outcome 
measures, sample size, statistical methods, estimate of vari-
ance, risk of bias/confounders, results, and conclusions. 
Three questions related to interventional study design were 
not considered. A summary score (%), ranging from zero 
(low quality) to 100 (high quality), was calculated for each 
study by one author (LVW). A minimum quality threshold 
for study inclusion was not determined, and hence studies 
were not excluded based on the quality assessment.
Data extraction
Data were extracted to develop a catalogue with the fol-
lowing information: disease, patient subgroup (e.g., disease 
stage), sample size, mean age, percentage men, EQ-5D 
score for the chronically ill patients and for the general and 
healthy population with corresponding standard deviation or 
standard error, country-specific scoring algorithm, EQ-5D 
version, disutility, country, and author. Diseases were 
grouped based on the International Statistical Classification 
of Diseases and Related Health Problems 10th Revision 
(ICD-10) classification [21]. When the corresponding ICD-
10 class was not clearly indicated, the disease was catego-
rized in the most appropriate disease group.
Disutilities demonstrate the impact of diseases in terms 
of ‘loss’ in EQ-5D. They reflect the difference between the 
EQ-5D scores of the general population and the patient 
population.
Results
Study selection
After deduplication, 10,545 articles were screened for rel-
evance based on title and abstract, resulting in 543 articles. 
After reading full texts, 187 articles remained eligible for 
inclusion. Examining the reference lists resulted in 20 addi-
tional studies. In total, 207 studies were included. Figure 1 
presents the flowchart of the literature search and study 
selection process.
Fig. 1  Flowchart of the litera-
ture search and study selection 
process
19,030 records identified through database searching:
MEDLINE (n=4519)
Embase (n=9638)
Web of Science (n=4873)
10,545 records identified after duplicate removal
Removed by Endnote (n=7646)
Removed by Rayyan (n=37)
Manually removed (n=802)
543 records identified after screening based on title/abstract
10,002 irrelevant records excluded
187 records identified after reading on full text
207 records included in systematic review 
356 full-text records excluded:
Conference abstract (n=133)
Design (n=5)
Duplicate (n=1)
Language (n=4)
No full text (n=14)
Outcome (n=150)
Population (n=49)
20 extra records included after 
screening of reference list
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Agreement between the two authors was determined 
using Cohen’s Kappa statistic and resulted in an interrater 
reliability of 0.77. The quality assessment demonstrated con-
siderable discrepancies in quality between studies. Overall, 
all studies appeared to have appropriate representations of 
the utility outcomes. Details of the quality assessment are 
illustrated in Online Resource 2.
Study characteristics
All studies found in this review were published between 
1999 and 2019 and were conducted in various countries 
worldwide. Most of the studies were performed in Europe 
(n = 121), specifically in the UK (n = 29), followed by Korea 
(n = 26), the USA (n = 17), and China (n = 13). Study popu-
lation varied in sample size (n = 1 to n = 233,124), gender 
(0% male to 100% male), and age (mean age = 21.4 to mean 
age = 82.0).
Most of the studies (87.4%) used the EQ-5D-3L, and 
only twenty-three (11.1%) used the EQ-5D-5L. Three stud-
ies (1.4%) did not mention the EQ-5D version that was 
used. The time trade-off scoring algorithm was used by 
77.3% to obtain the EQ-5D value set, whereas only 1.9% 
used the VAS scoring algorithm. Four studies (1.9%) used 
a crosswalk index value set for the EQ-5D-5L. A substan-
tial number of studies did not mention the scoring algo-
rithm (18.8%). Moreover, a wide range of country-specific 
value sets was used. Utilities for the reference population 
were mostly extracted from the literature, which often 
resulted in different scoring algorithms between patients 
and reference population.
Synthesis of findings
The EQ-5D index scores for all available chronic diseases 
compared to their reference values are summarized as a 
catalogue available in Online Resource 3.
Overall, the highest EQ-5D score was reported in obe-
sity with alcohol dependence and in lung cancer with 
chemotherapy (1.00), followed by alcohol abuse, diabetes, 
cancer, hypercholesterolaemia, and hypertension (0.97). 
The lowest EQ-5D score was reported in severe Alzhei-
mer’s disease (− 0.20) and multiple sclerosis (− 0.07). 
Likewise, the highest disutility was reported in severe 
Alzheimer’s disease (− 1.05). In contrast, the lowest dis-
utility was reported in non-small cell lung cancer with 
chemotherapy with a utility score 0.22 points higher than 
the general population.
Few studies (15.5%) used regression analysis to calcu-
late disutilities, adjusted for several covariates. The major-
ity of disutilities were calculated by the authors of this 
review because they were not mentioned in the original 
papers.
An overview per ICD-10 chapter of the lowest and high-
est mean EQ-5D scores and disutilities as they appeared in 
the original papers are provided in Table 1.
Table 1  Overview of the findings
Chronic disease chapter (ICD-10) Number of 
studies
Mean EQ-5D range Disutility range
Neoplasms 38 0.45 to 1.00 − 0.46 to + 0.22
Diseases of the blood and blood-forming organs and certain disorders involving the 
immune mechanism
4 0.65 to 0.92 − 0.07 to − 0.01
Endocrine, nutritional, and metabolic diseases 57 0.31 to 1.00 − 0.58 to + 0.11
Mental and behavioural disorders 46 0.11 to 0.97 − 0.68 to + 0.15
Diseases of the nervous system 41 − 0.20 to 0.92 − 1.05 to + 0.06
Diseases of the eye and adnexa 17 0.45 to 0.95 − 0.48 to + 0.01
Diseases of the ear and mastoid process 10 0.59 to 0.93 − 0.19 to − 0.00
Diseases of the circulatory system 50 0.30 to 0.97 − 0.66 to + 0.02
Diseases of the respiratory system 36 0.47 to 0.95 − 0.37 to + 0.03
Diseases of the digestive system 17 0.49 to 0.92 − 0.41 to + 0.01
Diseases of the skin and subcutaneous tissue 8 0.58 to 0.90 − 0.34 to − 0.00
Diseases of the musculoskeletal system and connective tissue 48 0.26 to 0.94 − 0.67 to + 0.10
Diseases of the genitourinary system 15 0.44 to 0.96 − 0.49 to + 0.01
Certain conditions originating in the perinatal period 1 0.84 − 0.09
Congenital malformations, deformations, and chromosomal abnormalities 5 0.19 to 0.92 − 0.67 to + 0.10
Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified 13 0.32 to 0.93 − 0.29 to + 0.08
Injury, poisoning and certain other consequences of external causes 7 0.37 to 0.88 − 0.49 to + 0.20
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Neoplasms
EQ-5D scores ranged from 0.45 for palliative breast cancer 
and non-small cell lung cancer with severe adverse event 
to 1.00 for non-small cell lung cancer with chemotherapy. 
Disutilities ranged from − 0.46 for colorectal cancer stage IV 
to + 0.22 for non-small cell lung cancer with chemotherapy.
Diseases of the blood and blood‑forming organs 
and certain disorders involving the immune mechanism
EQ-5D scores ranged from 0.65 for haematologic conditions 
to 0.92 for anaemia. Disutilities ranged from − 0.07 for hae-
matologic conditions to − 0.01 for anaemia.
Endocrine, nutritional, and metabolic diseases
EQ-5D scores ranged from 0.31 for diabetes with maximal 
major amputation to 1.00 for obesity with alcohol depend-
ence. Disutilities ranged from − 0.58 for diabetes with maxi-
mal major amputation to + 0.11 for male diabetic patients.
Mental and behavioural disorders
EQ-5D scores ranged from 0.11 for dementia to 0.97 for 
alcohol abuse. Disutilities ranged from − 0.68 for unspeci-
fied mental conditions to + 0.15 for dementia.
Diseases of the nervous system
EQ-5D scores ranged from − 0.20 for severe Alzheimer’s 
disease to 0.92 for epilepsy, convulsion, and Parkinson’s dis-
ease. Disutilities ranged from − 1.05 for severe Alzheimer’s 
disease to + 0.06 for relapsing–remitting multiple sclerosis.
Diseases of the eye and adnexa
EQ-5D scores ranged from 0.45 for visual dysfunction with 
comorbid stroke to 0.95 for age-related macular degenera-
tion. Disutilities ranged from − 0.48 for visual dysfunction 
with comorbid stroke to + 0.01 for age-related macular 
degeneration.
Diseases of the ear and mastoid process
EQ-5D scores ranged from 0.59 for patients ≥ 75 years with 
hearing impairment to 0.93 for patients ≥ 60 years with hear-
ing impairment. Disutilities ranged from − 0.19 for deafness 
to − 0.0 for ear disorder.
Diseases of the circulatory system
EQ-5D scores ranged from 0.30 for cerebral haemorrhage, 
cerebral infarction, and embolism to 0.97 for hypertension. 
Disutilities ranged from − 0.66 for cerebral haemorrhage, 
cerebral infarction, and embolism to + 0.02 for 1 year after 
acute coronary syndrome.
Diseases of the respiratory system
EQ-5D scores ranged from 0.47 for chronic airway obstruc-
tion to 0.95 for asthma. Disutilities ranged from − 0.37 for 
chronic bronchitis, chronic obstructive pulmonary disease, 
and emphysema to +0.03 for chronic obstructive pulmonary 
disease without comorbidities.
Diseases of the digestive system
EQ-5D scores ranged from 0.49 for pancreatic disorder to 
0.92 for ulcer. Disutilities ranged from − 0.41 for liver cir-
rhosis/dysfunction to + 0.01 for atrophic gastritis, Barrett 
oesophagus, and oesophagitis.
Diseases of the skin and subcutaneous diseases
EQ-5D scores ranged from 0.58 for chronic ulcer of skin to 
0.90 for pimples. Disutilities ranged from − 0.34 for skin 
disorder to − 0.00 for psoriasis and (inflammatory) skin 
disorder.
Diseases of the musculoskeletal system and connective 
tissue
EQ-5D scores ranged from 0.26 for juvenile idiopathic 
arthritis to 0.94 for arthritis. Disutilities ranged from − 0.67 
for severe fibromyalgia to + 0.10 for postmenopausal women 
with osteoporosis.
Diseases of the genitourinary system
EQ-5D scores ranged from 0.44 for renal failure with hae-
modialysis to 0.96 for chronic kidney disease stage one. 
Disutilities ranged from − 0.49 for urinary incontinence to 
+ 0.01 for chronic kidney disease stage one.
Certain conditions originating in the perinatal period
The EQ-5D score was 0.84 for survivors of bronchopulmo-
nary dysplasia with a disutility of − 0.09.
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Congenital malformations, deformations, 
and chromosomal abnormalities
EQ-5D scores ranged from 0.19 for tuberous sclerosis com-
plex with generalized convulsive seizure to 0.92 for aortic 
anomalies. Disutilities ranged from − 0.67 for tuberous scle-
rosis complex with generalized convulsive seizure to + 0.10 
isolated congenital aortic valve disease.
Symptoms, signs, and abnormal clinical and laboratory 
findings, not elsewhere classified
EQ-5D scores ranged from 0.32 for chronic neuropathic 
pain to 0.93 for not specified other chronic diseases. Disu-
tilities ranged from − 0.29 for dizziness with falls and pain 
to + 0.08 for chronic non-neuropathic pain.
Injury, poisoning, and certain other consequences 
of external causes
EQ-5D scores ranged from 0.37 for 2 weeks after hip frac-
ture to 0.88 for 12 months after wrist fracture. Disutilities 
ranged from − 0.49 for 2 weeks after hip fracture to + 0.20 
for 12 months after wrist fracture.
The findings confirm the lower HRQoL in patients with 
chronic diseases compared to the general population. Most 
of the diseases demonstrate a substantial disutility, although 
a minority of diseases had equal or even higher index scores 
than the general population.
Discussion
To our knowledge, this is the first systematic review that pro-
vides a comprehensive overview of the available literature 
on EQ-5D index scores for a large variety of chronic diseases 
compared with reference values from the general population. 
The focus of this review lies on all chronic non-communica-
ble disease chapters included in the ICD-10, which resulted 
in 207 included studies covering 308 different diseases. As 
a result, a large, international catalogue was developed with 
an extensive source of EQ-5D data. Since HRQoL has been 
prioritized as a key patient-reported outcome measure, the 
demand for these data is rising. This catalogue meets the ris-
ing demand from health economists for appropriate EQ-5D 
data that can be used in QALY calculations, but also from 
epidemiologists and policy makers to better understand the 
burden of chronic diseases [22, 23].
Our results confirm the substantial reduction in HRQoL 
associated with chronic diseases. Chronically ill patients 
have lower utility scores compared to the reference popu-
lation. More specifically, patients with neurological disor-
ders have the highest reduction in HRQoL, especially in 
Alzheimer’s disease. Moreover, the majority of studies focus 
on endocrine, nutritional, and metabolic diseases, mental 
and behavioural disorders, and diseases of the musculoskel-
etal and circulatory system.
A knowledge gap in the literature still exists for a few 
diseases, despite the fact that this review covers all chronic 
disease chapters in the ICD-10. For example, no data were 
available for cystic fibrosis, sleep apnoea, or specific types 
of cancer such as pancreatic cancer or bone cancer, although 
literature demonstrated their impact on HRQoL [24–28]. 
There is also little evidence about certain conditions origi-
nating in the perinatal period, diseases of the blood, and 
congenital malformations. Moreover, few studies reported 
on young adults whereas most studies focused on older 
populations. This can be explained by the fact that chronic 
diseases mainly occur in the elderly [29, 30]. Additionally, 
research originating from South America, Africa, and Aus-
tralia is lacking.
In this review, substantial differences in index scores for 
similar disease conditions were observed. For example, an 
index score of − 0.07 is reported for multiple sclerosis by 
one study, while another study reported a score of 0.90. This 
is also observed for dementia with scores ranging from 0.11 
to 0.90. Possible explanations to these variations are differ-
ences in study quality and methodology such as population 
characteristics, disease severity, scoring algorithm, EQ-5D 
version, and random measurement error [31]. Furthermore, 
scores vary according to gender. Several studies stratify the 
scores by gender with men having higher scores. This result 
is also seen in the general population [32, 33]. A possible 
explanation can be found in women’s extraversion when 
rating their health, resulting in more realistic scores than 
men [34]. Likewise, studies show that women have more 
comorbidities, and hence women’s HRQoL is often more 
impaired than men.
This study has several major strengths. It is unique in 
its kind, since it is the first study that summarizes mean 
EQ-5D scores for a wide range of chronic diseases across 
countries addressing the rising demand for HRQoL data [22, 
23]. In this regard, Sullivan et al. developed two high-quality 
catalogues with nationally representative preference-based 
HRQoL scores for chronic conditions [15, 31]. Despite 
their extensive work, the scope of Sullivan’s work is still 
quite limited given its national character. In response, our 
study has included a large number of international studies 
in which every continent, except Antarctica, is represented 
with Europe, Asia, and North America having the largest 
number of studies. The majority of studies originate from 
the UK, Sweden, and Korea. This global spread results in 
an extensive source of data useful for researchers world-
wide. Another strength is the broad range of chronic dis-
eases. Most studies collected information on one particular 
disease, impeding comparison with other diseases [35]. 
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In this view, our review can be regarded as innovative by 
including a large number of both common and rare diseases. 
Another strength is the inclusion of both EQ-5D versions, 
although a thorough comparability between both is not desir-
able due to differences in responses and valuation system. 
Therefore, the catalogue clearly mentioned the EQ-5D ver-
sion to avoid misinterpretation. Currently, the EQ-5D-5L is 
already widely used, but yet the EQ-5D-3L will remain part 
of the evidence base for many years, specifically due to its 
value sets [36]. Furthermore, many studies were screened on 
full text to avoid the risk of inadequate exclusion since the 
majority of studies report index scores as a small second-
ary outcome. A final important strength is the inclusion of 
reference values in each study, which allows us to assess the 
impact of a given disease, since a sole index value without 
reference is difficult to interpret.
However, caution is needed when interpreting the results 
because of the heterogeneity in quality of the studies. In 
some studies, there is a lack of sample size information 
and demographic information, such as age and gender. In 
addition, most studies did not clearly state disease severity 
or stage, disease duration, whether or not the disease was 
self-reported, and whether or not they followed active treat-
ment. The latter is very important to take into account since 
research showed that receiving treatment has a significant 
impact on patients’ HRQoL [37]. Furthermore, other deter-
minants such as socio-economic class, country of origin, and 
country of residence are worth to be mentioned as these can 
be a source of heterogeneity in the results. Due to practical 
restrictions, this review could not include all determinants 
in the catalogue.
Additionally, several studies have not reported which 
scoring algorithm was used. It is confirmed that the selection 
of scoring algorithm influences the index score [38]. Utility 
scores might differ substantially between countries because 
they reflect the preferences of the country of elicitation [39, 
40]. This may confound comparison across studies or dis-
eases [35]. Moreover, careful consideration is needed when 
interpreting the disutility values as some studies provide dis-
utilities based on regression analysis, whereas for the major-
ity a simple subtraction of the mean values was performed. 
A final caution is needed when interpreting the index scores 
in patients with dementia or with Alzheimer’s disease. These 
scores are often filled in by proxy and may bias the patients’ 
index scores. These findings underline the importance of 
investigating study characteristics and patients’ demographic 
background to interpret results properly.
Another limitation is the lack of information about 
whether or not significant differences in EQ-5D index scores 
exist between chronically ill patients and the general pop-
ulation. The majority of studies did not perform statistics 
to investigate significance, and therefore only disutilities 
without details about the significance level were described. 
Selecting studies based on reported significance level would 
have resulted in less included studies. Furthermore, there 
is a lack of information on whether or not the utilities are 
age-standardized. Hence, comparison between scores is 
difficult because the disease groups being compared may 
differ significantly with respect to demographic characteris-
tics. Another limitation is the exclusion of median utilities. 
Although both are mathematically valid point estimates, 
the use of means is recommended by health economists 
[41]. Experimental studies were excluded because they are 
often not representative for a given disease group; however 
by excluding these, some useful findings could have been 
missed.
This review is limited to the EQ-5D because it is interna-
tionally recognized as the most widely used instrument for 
obtaining health utilities. Other valuable measures, such as 
the SF-36 or Health Utilities Index (HUI), were not included 
but can be of importance for health economic evaluations. 
However, caution is needed since literature confirms that 
outcomes of various instruments are not interchangeable 
[42].
In conclusion, this study is the first to provide a com-
prehensive overview of published EQ-5D index scores in 
chronic diseases. By making the catalogue publicly avail-
able, researchers will no longer have to collect primary 
EQ-5D data that can be used for different applications such 
as cost-effectiveness analysis, decision making, and resource 
allocation. To enlarge evidence on HRQoL in chronic dis-
eases, further investigation on unexamined diseases is 
required and more attention to specific patient groups is 
essential.
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